Posted by Michael Wonder on 13 Dec 2019
Highlights from the December 9-12 CHMP meeting
13 December 2019 - EMA’s human medicines committee (CHMP) recommended five medicines for approval at its December 2019 meeting.
The Committee recommended granting a marketing authorisation for Beovu (brolucizumab) for the treatment of neovascular (‘wet’) age-related macular degeneration, a disease that affects the central part of the retina at the back of the eye and causes loss of ‘straight-ahead’ vision.
The CHMP adopted a positive opinion for Recarbrio (imipenem with cilastatin and relebactam), for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.
